FDA gives first approval for recurrent respiratory papillomatosis therapy
This is the second therapy available, expanding options beyond surgery and the limited use of interferon marketed in Russia.
This is the second therapy available, expanding options beyond surgery and the limited use of interferon marketed in Russia.